Bubici C, Papa S, Dean K, Franzoso G
The Ben May Institute for Cancer Research, The University of Chicago, Chicago, IL 60637, USA.
Oncogene. 2006 Oct 30;25(51):6731-48. doi: 10.1038/sj.onc.1209936.
Reactive oxygen species (ROS) are emerging as key effectors in signal transduction. This role of ROS is especially evident in the pathways leading to programmed cell death (PCD) elicited in response to certain stress stimuli and cytokines. In these pathways, cytotoxic ROS signaling appears to be mediated in part by activation of the c-Jun-N-terminal kinase (JNK) mitogen-activated protein kinase (MAPK) cascade. Another pathway that is under ROS-mediated control in some systems is that leading to activation of transcription factor nuclear factor-kappa B (NF-kappaB), which is a central regulator of immunity, inflammation and cell survival. Remarkably, new evidence has unveiled the existence of a reciprocal, negative control that NF-kappaB exerts on ROS and JNK activities. This NF-kappaB-imposed restraint on ROS and JNK signaling is crucial for antagonism of PCD elicited by the proinflammatory cytokine tumor necrosis factor (TNF)alpha and likely other triggers. Effectors of this antagonistic cross-talk between NF-kappaB and ROS/JNK pathways have recently been identified. Because of the key roles that the prosurvival function of NF-kappaB plays in organismal physiology and disease, gaining a further mechanistic understanding of this cross-talk and NF-kappaB-dependent survival may be key to developing new therapies for the treatment of widespread human illnesses, such as cancer and chronic inflammatory conditions.
活性氧(ROS)正逐渐成为信号转导中的关键效应分子。ROS的这一作用在因某些应激刺激和细胞因子引发的程序性细胞死亡(PCD)途径中尤为明显。在这些途径中,细胞毒性ROS信号似乎部分是由c-Jun氨基末端激酶(JNK)丝裂原活化蛋白激酶(MAPK)级联反应的激活介导的。在某些系统中,另一条受ROS介导控制的途径是导致转录因子核因子-κB(NF-κB)激活的途径,NF-κB是免疫、炎症和细胞存活的核心调节因子。值得注意的是,新证据揭示了NF-κB对ROS和JNK活性存在一种相互的负调控。NF-κB对ROS和JNK信号的这种抑制作用对于拮抗促炎细胞因子肿瘤坏死因子(TNF)α及可能的其他触发因素引发的PCD至关重要。最近已经确定了NF-κB与ROS/JNK途径之间这种拮抗相互作用的效应分子。由于NF-κB的促存活功能在机体生理和疾病中发挥的关键作用,进一步从机制上理解这种相互作用以及NF-κB依赖性存活可能是开发治疗广泛人类疾病(如癌症和慢性炎症性疾病)新疗法的关键。